5 Stocks to Watch: Week of 1/12/2026

Happy weekend to you! We won’t keep you for long — just checking in to deliver a curated selection of the best stocks from our Zen Ratings system to watch for the coming week, including:

• Analysts believe Supernus Pharmaceuticals (SUPN) has a strong trajectory ahead
• Broadcom (AVGO) is back in the hot seat (in a good way)
• Amneal Pharmaceuticals (AMRX) is our Stock of the Week — for the second time in a month! 
• Blue Bird (BLBD) drives a different sort of EV revolution 
• Super Group (SGHC) benefits from a thriving and growing market

And if you missed last week's picks, you can get them here.

A note from our sponsors...

1- Broadcom (NASDAQ: AVGO)

Broadcom is a major AI infrastructure beneficiary with record AI semiconductor revenues growing 74% year-over-year, driven by hyperscaler demand and new customers including Anthropic and xAI.

Zen Rating: B (Buy) — see full analysis

Recent Price: $340.44 — get current quote

Max 1-year forecast: $510.00

Why we're watching:

• Analyst support: The stock has overwhelming support from the analysts we track, with 16 Strong Buy ratings, 5 Buy ratings, and just 1 Hold out of 22 total analysts. See the ratings
• For example, Truist Securities' William Stein (a top 1% rated analyst) recently maintained his Strong Buy rating with a $510 price target, representing +46.71% upside potential and the highest target among all analysts.
• Speaking of top-tier analysts, UBS's Timothy Arcuri (a top 1% rated analyst) and Morgan Stanley's Joseph Moore (also top 1%) both recently maintained Strong Buy ratings. 
• Analysts are particularly confident in Broadcom's focus on AI accelerators and networking, with Q1 2026 AI semiconductor revenues projected to reach $8.2B, driven by major clients like Google and Meta Platforms.
• CEO commentary highlighted that Q4 record revenue of $18B grew 28% year-over-year, driven primarily by AI semiconductor revenue increasing 74% year-over-year, with expectations for AI semiconductor revenue to double year-over-year to $8.2B in Q1 2026. 
• Industry ranking context: AVGO is currently the 6th highest-rated stock out of 69 in the Semiconductor industry, which has an Industry Rating of C.
• Zen Rating highlights: Buy (B) stocks in our quant ratings system have historically averaged +19.88%/yr — but AVGO’s price targets suggest it could exceed this benchmark. 
• Component Grades: The stock shows particular strength in Financials, Sentiment, and Momentum, and from our proprietary AI rating (all above-average B grades). See all 7 Zen Component Grades here

2- Super Group (NYSE: SGHC)

Super Group is drawing growing analyst buzz as a well-positioned play on the expanding global online gambling market, with meaningful upside potential ahead.

Zen Rating: B (Buy) — see full analysis

Recent Price: $10.58 — get current quote

Max 1-year forecast: $20.00

Why we're watching:

• SGHC currently has unanimous bullish sentiment among the analysts we track, with 3 Strong Buy ratings and 3 Buy ratings from 6 analysts covering the stock. See the ratings
• For example, BTIG researcher Clark Lampen (top 7%) recently maintained a Strong Buy rating with a $20 price target, highlighting the company's growth trajectory in international markets. This price target suggests +67.93% upside potential. 
• Benchmark's Mike Hickey (top 4%) recently maintained his Strong Buy rating with a $17 price target, emphasizing the company's disciplined market expansion strategy.
• Industry ranking context: SGHC is in the Gambling industry, which has an Industry Rating of B. It's currently the 2nd highest-rated stock in this above-average Industry.
• Zen Rating highlights: Buy or B-rated stocks in our Zen Ratings system are no joke. They’ve historically returned 19.88% over the past 20 years — so they’re worth watching, particularly when positioned in a trending industry. 

Component Grades: Super Group demonstrates balanced performance with B ratings in Sentiment and Safety. See all 7 Zen Component Grades here

A note from our sponsors...

3- Supernus Pharmaceuticals (NASDAQ: SUPN)

Supernus Pharmaceuticals focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company is gaining momentum with its Onapgo continuous subcutaneous infusion pump for advanced Parkinson's disease, which analysts believe has a promising trajectory.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $51.45 — get current quote

Max 1-year forecast: $65.00

Why we're watching:

• SUPN has a bullish consensus among the analysts we track — 4 Strong Buy ratings and 1 Hold rating from 5 analysts covering the stock. See the ratings
• Cantor Fitzgerald's Kristen Kluska (a top 2% rated analyst) maintains a Strong Buy rating with a $63 price target, representing +27.53% upside potential.
• Piper Sandler researcher David Amsellem (top 6%) upgraded to Strong Buy with a $65 price target, noting that Onapgo has a promising trajectory and is not heavily dependent on promotions, which bodes well for the company's ability to expand margins and increase EBITDA.
• Industry ranking context: SUPN is currently the 10th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
• Zen Rating highlights: As an A or Strong Buy-rated stock in the Zen Ratings system, SUPN is in the top tier of the stocks we track — A-rated stocks have historically generated 32.52% average annual returns for the past 20+ years. 
• Component Grades: Supernus shows outstanding performance with an A in Artificial Intelligence and B grades across Value, Growth, Sentiment, and Safety, indicating innovative capabilities and balanced fundamentals, though Financials receive a C grade. See all 7 Zen Component Grades here

4- Blue Bird (NASDAQ: BLBD)

Blue Bird Corporation is driving the electric school bus revolution, riding powerful replacement demand and accelerating adoption of alternative-power fleets.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $47.44 — get current quote

Max 1-year forecast: $76.00

Why we're watching:

• The 4 analysts we follow issuing ratings on BLBD are pretty psyched on the stock — it has 3 Strong Buy and 1 Buy rating. See the ratings
• For instance, BTIG researcher Gregory Lewis (a top 4% rated analyst) recently reiterated a Strong Buy rating with a $65 price target, representing +36.01% upside potential. That update came following the company's strong Q4 and FY 2025 results. 
• By the way, speaking of earnings, BLBD has exhibited a fantastic track record of past earnings growth, to the tune of +54.88% / yr over the past 5 years. 
• Industry ranking context: Here’s the bad news about BLBD — it’s in an F rated industry, indicating the industry faces serious headwinds. However, BLBD is currently the 1st highest-rated stock in the Auto industry, and its Zen Rating and Component Grades make its outperformance particularly notable.
• Zen Rating highlights: BLBD has an A or Strong Buy rating. In addition to representing the top echelon of the 4600+ stocks we track, this puts BLBD in a category of stocks that have historically trounced the S&P. 
• Component Grades: Blue Bird shows standout performance with A ratings in Value and Financials, reflecting attractive valuation and strong operational metrics, though Safety receives a D, warranting attention to risk factors. See all 7 Zen Component Grades here

5- Amneal Pharmaceuticals (NASDAQ: AMRX)

Amneal Pharmaceuticals is our Stock of the Week — for the second time in a month. The company recently received FDA approval for Denosumab biosimilars and is expanding its specialty injectable drug portfolio with significant growth opportunities ahead. See below for more great reasons to watch this promising ticker. 

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $12.66 — get current quote

Max 1-year forecast: $15.00

Why we're watching:

• Analyst support: The stock has unanimous support with 3 Strong Buy ratings from all covering analysts, reflecting strong conviction in the stock. See the ratings
• For example, Piper Sandler's David Amsellem (a top 6% rated analyst) recently reiterated his Strong Buy rating with a $13 price target based on improving market conditions for generic pharmaceuticals.
• It’s also been featured as our Stock of the Week twice in the past month. For a more detailed breakdown of AMRX’s positive attributes, check out this video. 
• The company's portfolio expansion includes recent FDA approvals for Denosumab biosimilars referencing Prolia and XGEVA, as well as Epinephrine injection for U.S. hospitals, strengthening its competitive position.
• Industry ranking context: AMRX is currently the 3rd highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of A.
• Zen Rating highlights: With its Strong Buy (A) rating, AMRX is in a class of stocks that have historically trounced the S&P with 32.52% average annual returns. 
• Component Grades: The stock shows comprehensive strength with Value at B grade, Growth at B reflecting strong earnings trajectory, Sentiment at A grade, and Momentum at B as the stock approaches 52-week highs. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.